IPP Bureau
Amgen and Arrakis collaborate for small molecule therapeutics
By IPP Bureau - January 12, 2022
Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen
Indian pharma industry registers 5.3% YoY revenue growth in Dec 2021 : Ind-Ra
By IPP Bureau - January 12, 2022
Ind-Ra expects revenue growth of over 12% in 2022.
Marksons Pharma receive final US. FDA approval for Cetirizine Hydrochloride tablets
By IPP Bureau - January 12, 2022
The product will be marketed under store brand labels and is comparable to the brand Zyrtec
Sinocompound and InCatT launch new Catalyst Screening Service
By IPP Bureau - January 12, 2022
This service benefits pharmaceutical and fine chemical companies looking to optimise their reactions
Alkem Labs to launch treatment for Diabetic Foot Ulcer
By IPP Bureau - January 12, 2022
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
ABL Bio collaborates with SANOFI for Parkinson’s antibody
By IPP Bureau - January 12, 2022
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease
Covaxin booster neutralises Omicron and Delta variants: Study
By IPP Bureau - January 12, 2022
The study will be published on the pre-print server, medRXiv, shortly
Wacker and Biosyntia to develop production process for sustainable biotin
By IPP Bureau - January 11, 2022
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer
By IPP Bureau - January 11, 2022
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
Pfizer and Beam enter research collaboration for In Vivo base editing programme
By IPP Bureau - January 11, 2022
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
Takeda to acquire Adaptate Biotherapeutics
By IPP Bureau - January 11, 2022
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
Immune Biosolutions lead immunotherapy product neutralises Covid-19
By IPP Bureau - January 11, 2022
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Prof. Jason Kovacic bags Agilent Thought Leader award
By IPP Bureau - January 11, 2022
Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease
Molnupiravir best option to treat Covid-19 now: Experts
By IPP Bureau - January 11, 2022
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Intuitive India launches Intuitive Telepresence for remote surgical case observation
By IPP Bureau - January 11, 2022
Intuitive Telepresence (ITP), facilitates remote learning, and encourages interaction and collaboration between surgeons without the need to travel
